A strategy is proposed in which intrafraction internal target translation is corrected for by repositioning the multileaf collimator position aperture to conform to the new target pose in the beam projection, and the beam monitor units are adjusted to account for the change in the geometric relationship between the target and the beam. The purpose of this study was to investigate the dosimetric stability of the prostate and critical structures in the presence of internal target translation using the dynamic compensation strategy. Twenty-five previously treated prostate cancer patients were replanned using a four-field conformal technique to deliver 72 Gy to 95% of the planning target volume ͑PTV͒. Internal translation was introduced by displacing the prostate PTV ͑no rotation or deformation was considered͒. Thirty-six randomly selected isotropic displacements of magnitude 0.5, 1.0, 1.5 and 2.0 cm were sampled for each patient, for a total of 3600 errors. Due to their anatomic relation to the prostate, the rectum and bladder contours were also moved with the same magnitude and direction as the prostate. The dynamic compensation strategy was used to correct each of these errors by conforming the beam apertures to the new target pose and adjusting the monitor units using inverse-square and off-axis factor corrections. The dynamic compensation strategy plans were then compared to the original treatment plans via dose-volume histogram ͑DVH͒ analysis. Changes of more than 5% of the prescription dose ͑3.6 Gy͒ were deemed clinically significant. Compared to the original treatment plans, the dynamic compensation strategy produced small discrepancies in isodose distributions and DVH analyses for all structures considered apart from the femoral heads. These differences increased with the magnitude of the internal motion. Coverage of the PTV was excellent: D 5 , D 95 , and D mean were not increased or decreased by more than 5% of the prescription dose for any of the 3600 simulated internal motion shifts. Dose increases for adjacent organs at risk were rare. D 33 of the rectum and D 20 of the bladder were increased by more than 5% of the prescription dose in 9 and 1 instances of the 3600 sampled internal motion shifts, respectively. D mean of the right femoral head increased by more than 5% of the prescription dose in 651 ͑18%͒ internal motion shifts, predominantly due to the projection of the lateral beams through the femoral head for anterior prostate motion. However, D 2 was not increased by more than 5% for any of the internal motion shifts. These data demonstrate the robustness of the proposed dynamic compensation strategy for correction of internal motion in conformal prostate radiotherapy, with minimal deviation from the original treatment plans even for errors exceeding those commonly encountered in the clinic. The compensation strategy could be performed automatically with appropriate enhancements to available delivery software. © 2007 American Association of Physicists in Medicine.
I. INTRODUCTION
In the living body, the skeletal, respiratory, cardiac, gastrointestinal, and genitourinary systems cause internal motion. The broad aim of the research project is to account for this motion using dynamic compensation. This work focuses on realigning the multileaf collimator ͑MLC͒-defined radiation beam with prostate motion continuously in an online setting, for example, tracking implanted fiducials. 1 The prostate has been observed to move with time using radiographic and nonradiographic methods with the dominant motion being anterior-posterior ͑AP͒ and superior-inferior. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Padhani et al. 9 used cine magnetic resonance imaging to measure prostate motion over a single 7-min. period in 55 patients. Prostate movements in the AP direction were seen in 16 patients, and in nine patients the movement was greater than 5 mm. The median prostate AP displacement was anterior by 4.2 mm ͑−5 to + 14 mm͒. Ghilezan et al. 8 conclude that the most significant predictor for intrafraction prostate motion is the status of rectal filling. This internal motion can be corrected for by aligning the beam with the target. The beam and target can be aligned by moving the patient via couch motion, 12 or moving the beam via MLC adjustment, [13] [14] [15] [16] [17] [18] [19] [20] [21] robotic adjustment 22, 23 or block motion. 24 Moving the patient ͑couch motion͒ to account for internal motion may induce secondary skeletal motion. Of the beam moving options, the MLC is the most widely available, and the ability to control individual leaf positions means it has the largest number of degrees of freedom to account for rotation or deformation ͑not considered in this study͒. Using an intrabeam correction strategy, Litzenberg et al. 10 estimated that intrabeam prostate tracking could yield clinical target volume ͑CTV͒-planning target volume ͑PTV͒ margins of ഛ1.5 mm.
When the target moves with respect to the skeletal anatomy, the quality of the treatment plan designed on the pretreatment CT scan may degrade for the target position at the time of treatment, even if the beam aperture is moved to coincide with the per-beam target position. The internal motion results in changes in the source-to-target distance and the off-axis distance of the target; thus, monitor-unit ͑MU͒ adjustments may be needed to maintain acceptable dosimetric target coverage.
A previous study related to this work focused on the robustness of a method to account for detected patient misalignment by moving the MLC rather than moving the patient, i.e., accounting for setup error by moving the beam rather than the patient. 25 This work focuses on using a similar method to account for internal motion. Combining the use of the MLC to dynamically compensate for the geometric effects of detected internal motion with a method to account for the MU adjustments to compensate for the dosimetric effects of intrafraction target translation is the focus of this work. The overall aim of this study was to determine the dosimetric stability of the prostate and critical structures in the presence of internal target translation for an MLC-based dynamic compensation strategy.
II. METHODS AND MATERIALS
This section describes the method of adjusting the beam aperture and the MUs and how the dynamic compensation strategy was tested. The strategy studied is shown in Fig. 1 , where detected motion is compensated geometrically by adjusting the beam aperture and dosimetrically by adjusting the MUs for the beam. Note that the feedback loop is developed for intrafraction motion, while the results shown are for total treatments at a given internal motion value. The summation of the dose per fraction, resulting from known internal motion within a fraction ͑in the absence of deformation͒, is simply a time ͑dose͒ integral. Thus, the results presented here are for a "worst" case scenario, assuming that the internal motion was present for the entire treatment.
In the treatment scenario simulated, the CT anatomy at simulation is known, and the geometric relationship of the target to the bony anatomy is known throughout the treatment fraction, using, for example, intratreatment radiographic imaging of implanted markers [1] [2] [3] [5] [6] [7] 26, 27 or localization of electromagnetic transponders.
10

A. CT data and treatment planning
The CT data and treatment planning in the absence of motion have been discussed in a previous study on compensating for daily patient-positioning errors ͑as opposed to internal target motion, which is studied here͒. 25 Briefly, the CT scans of 25 patients were used. The clinical target volumeconsisting of the prostate and proximal seminal vesicles, rectum, periprostatic rectum, and femoral heads-were segmented. To account for rotation and deformation of the prostate during the course of radiotherapy, a planning target volume was derived by expanding the CTV by 0.6 cm posteriorly and 1.0 cm in all other dimensions, with PTV-toblock margins of 0.5 cm radially and 1.0 cm superiorly and inferiorly. 28 A MLC was used for the field blocking. A fourfield plan was created using 18-MV photons with anteriorposterior and lateral fields. Monitor units were set so that at least 95% of the PTV received the prescription dose of 72 Gy in 36 fractions. The plans were not altered in any way to limit the dose to adjacent organs at risk ͑OARs͒.
B. Simulating internal motion
The internal motion was simulated by translating the PTV, bladder, and rectum by a vector of fixed magnitude. Internal motion values of 0.5, 1.0, 1.5, and 2.0 cm were considered, to span the range of published motion. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] The direction of the translation vector was sampled uniformly over 4 steradians, yielding isotropic internal motion. Though the prostate has been observed to move little in the lateral direction, this component was included because it encompassed previously measured motion data and may provide some insight ͑albeit limited͒ regarding the general applicability of dynamic compensation for other sites. Thirty-six samples ͑1 per 2-Gy fraction͒ for each internal motion value for each patient were studied, totaling 3600 computed dose distributions. No rotation or deformation of the target, rectum or bladder was explicitly considered ͑the CTV-to-PTV margin accounts for target rotation and deformation͒. The assumption that the rectum and bladder move and do not deform in the presence of motion is obviously an approximation. The impact on a DVH of changes of shape, size, and position of the rectum The treatment-beam aperture and monitor units were continuously updated based on the information from a patient-positioning system. For the purposes of the study, the internal motion shift was assumed to be constant throughout the treatment-a worst case scenario from a dosimetric point of view. The required information for the geometric and dosimetric correction, not generally available at treatment, is the target position with time and the planning target volume from planning.
and bladder are not easily predictable due to the fact that the entirety of the organ volume may move towards regions of low doses or high doses. 29 Given that most prostate treatments are currently based on a single CT image, including more accurate estimations using deformable registration methods is not possible. Thus, the remaining option, which is perhaps worse than assuming the structures move together, is not moving the critical structures and thus introducing unrealistic scenarios such as the prostate moving into the bladder.
C. Geometric compensation: Beam aperture adjustment
The geometric correction strategy is shown in Fig. 2 , where the target moves with respect to the skeletal anatomy, and the beam is adjusted accordingly. Dynamic compensation consisted of MLC adjustments to conform to the altered PTV position and to the associated beam-view projection, due to the slightly different pose in the beam view, and the MU changes described below. The gantry angle remained fixed. In principle, collimator and gantry angles could change as well to partially compensate for target rotations; however, since target rotations were not simulated here, these angles remained fixed.
D. Dosimetric compensation: Monitor unit adjustment
The scenario of a rigid body moving inside fixed skeletal anatomy irradiated by a beam following the target motion introduces some fundamental dosimetric changes which can be corrected, to first order, by applying appropriate modifications to the MUs for each beam. The magnitude of the dosimetric corrections is small ͑Ͻ5% per beam for up to 2 cm of internal motion͒; however, the computational burden of including this information, which improves the overall accuracy, is also small and thus worthy of inclusion.
If the target moves parallel to the beam direction, inverse square ͑ISQ͒ corrections can be applied to reduce the dosimetric effect of the motion. If the target moves perpendicular to the beam direction, off-axis factors ͑OAFs͒ can be applied for dosimetric correction. These two factors were adjusted for in this work, as described previously for setup error correction. 25 A new factor introduced when accounting for internal motion is that if the target moves with respect to the skeletal anatomy, there will be differing amounts of overlying tissue between the target and the beam. Internal motion can also cause changes in pathlength due to density changes between the target and the beam source, e.g., if the beam, moving to cover the shifted PTV, passes through more of the femoral head. Changes in the external surface contour during treatment would also affect the pathlength. These pathlength corrections were not included in the current study. Similarly, the dosimetric effects of field-size correction factor ͑FSCF͒ are not accounted for. This may occur, for example, when the target moves proximally towards the beam, thereby rendering an apparent magnification of the PTV in the beam view. In the current study, the geometric effects of this magnification are included in the beam-aperture modification. The error would then be the ratio of the FSCF of the magnified beam aperture to that of the original FSCF. As the FSCF function is relatively flat, this error is likely to be small.
E. Dosimetric evaluation
The plans generated for each of the 3600 internal motion shifts corrected using dynamic compensation were compared with the original treatment plans via dose-volume histogram ͑DVH͒ analysis. Mean dose and dose-volume points for various structures were used in the comparison. Changes of greater than 5% of the prescription dose ͑3.6 Gy͒ were considered significant, based on earlier studies that report that 3% to 7% changes in the dose delivered are measurable through clinical observations. [30] [31] [32] [33] [34] Throughout this manuscript, D x is defined as the dose to x% of volume of the region of interest ͑ROI͒, and D mean is the mean dose of the ROI.
Planning target volume coverage was deemed adequate if D 5 , D 95 , and D mean ͑mean dose͒ changed by Ͻ5% of the prescription dose when compared with the couch-corrected treatment plans. Similarly, for organs at risk ͑OARs͒, an increase of Ͼ5% of the prescription dose for any mean dose or evaluated point dose was considered significant. The OARs included bladder ͑D 2 , D 20 , and D mean ͒, rectum and periprostatic rectum ͑D 2 , D 33 , D mean ͒, and the right femoral head ͑D 2 , D 10 , and D mean ͒. Doses for the left femoral head were calculated but are not displayed here, given that symmetry was observed in most cases; the exceptions were two cases in which the patients had left hip prostheses. For each internal motion corrected using dynamic compensation, the average change of each DVH parameter above was also calculated to determine trends of over-or underdosing.
III. RESULTS
Isodose distributions for both the original plan and the plan corrected for internal motion, for an example patient are shown in Fig. 3 , in which a 2-cm posterior/left internal motion shift is simulated. The relationship of the dose distribu- tion to the target in both cases is similar, though differences are observed for the femoral heads due to the projection of the beams through these structures, which change as the target moves.
Dose-volume histograms for the same patient are shown in Fig. 4 for each of the internal motion shifts considered.
The DVH without internal motion is shown with a solid curve. The DVHs for each of the sampled curves with internal motion are given by dotted lines. In general, the variation in DVHs increases with internal motion magnitude. Coverage of the PTV remains consistent, particularly at the prescription point ͑D 95 ͒. Similarly, the DVH curves of the bladder, rectum and periprostatic rectum ͑all assumed to move with the PTV͒ are similar to the curves in the absence of motion. With motion, the maximum PTV, rectum, and periprostatic rectum doses are slightly higher than the doses when motion is absent, perhaps indicating the limitation of the first-order dosimetry corrections performed here. Marked variation in the femoral head dose ͑though not maximum dose͒ is seen due to the varying projection of the beams through the femoral heads.
The DVH point data for all of the patients is given in Table I . Compared with the original treatment plans, the dynamic compensation strategy produced small discrepancies in isodose distributions and DVH analyses for all structures considered, apart from the femoral heads. These differences increased with the magnitude of internal motion. Coverage of the PTV was excellent: D 5 , D 95 , and D mean were not increased or decreased by more than 5% of the prescription dose for any of the 3600 simulated internal motion shifts. Dose increases for adjacent OARs were rare. D 33 of the rectum and the periprostatic rectum was increased by more than 5% of the prescription dose in nine and one instances of the 3600 sampled internal motion shifts, respectively. There were nine increases of the bladder D 20 of more than 5% of the prescription dose. D mean of the right femoral head increased by more than 5% of the prescription dose in 651 ͑18%͒ internal motion shifts, predominantly due to the projection of the lateral beams through the femoral head for anterior prostate motion. However, D 2 was not increased by more than 5% for any of the internal motion shifts.
The distribution of the dose-volume parameters is displayed in Fig. 5 . As expected, the spread of the distribution increases with internal motion, as the variation in position for the different internal motion magnitudes becomes larger. However, the spread is still relatively small ͑Ͻ2% ,1͒, except for the femoral heads. The mean of the distributions is also nonzero and increases as the internal motion magnitude increases. A possible cause is the approximations made in the dosimetric correction used for each beam.
IV. DISCUSSION
The study investigated a method of dynamic compensation for internal motion of the prostate treated with conformal radiotherapy. The results show that the dose distribution of the structures assumed to move together-the PTV, rectum, and bladder-was insensitive to the motion if corrected, with the magnitude of the discrepancy increasing with internal motion. However, the dose distributions of the anatomy assumed to be static, the femoral heads, differed significantly with respect to the internal target motion. This variation is unavoidable under any motion-compensation strategy. As the distance between structures changes, different projections of the beam through the fixed structures result in different dose distributions. Reducing both the systematic and random components of internal motion during treatment opens the space for significant CTV-PTV margin reduction.
The work presented here is a simulation study only and is a step towards online image-guided adaptive radiotherapy for three-dimensional ͑3D͒ conformal therapy treatments without requiring expensive in-room volumetric imaging. To implement this method into practice, the information required at the delivery console for beam adjustment would be: ͑1͒ the pose of the PTV such that the appropriate aperture is calculated when internal motion is detected, ͑2͒ the internal motion signal, and ͑3͒ a feasible MLC control method. Though the combination of these tools is not yet available at delivery to allow dynamic compensation, all of this information can be available; there are no roadblocks to clinical implementation, apart from putting the information together and developing appropriate quality assurance strategies. For example, for point ͑1͒, the pose of the PTV under translation is a simple ray-tracing calculation. The internal motion signal for ͑2͒ could be the signal from implanted markers given by orthogonal x-ray imagers 26,27,35 or electromagnetic tracking. 10, [36] [37] [38] Regarding ͑3͒, a feasible MLC control system, the published one-dimensional motion tracking efforts 21 have recently been extended to tracking motion in 3D and demonstrated geometrically and dosimetrically for CRT and IMRT fields ͑results not shown͒. Based on MLC velocity and acceleration measurements 39 and response time measurements of 160 ms, 21 the dynamic compensation strategy is on a small time scale compared with intrafraction prostate motion. Small dosimetric errors may occur in the time between motion and response, but for a 160 ms response time, this is less than 1 MU at 600 MU/ min. This control method is not yet ready for clinical implementation, but the preliminary data indicate no major barrier to patient application.
A more complex dosimetric strategy than that proposed would require the entire treatment plan to be available at the treatment-delivery workstation to continuously calculate the beam apertures and MUs and to pass this information to the linear accelerator. This method, though appealing in that dosimetric stability would be further ensured, is computationally more intensive and further from implementation.
In terms of clinical relevance, Ghilezan et al. 40 estimate from their planning study that in the absence of organ motion and deformation 5% to 41% ͑average 13%͒ increases in maximum dose are possible. Litzenberg et al. 10 estimate, based on their prostate motion data, that intrabeam prostate tracking could yield CTV-PTV margins of ഛ1.5 mm. Thus, by combining image-guided setup with internal motion tracking, highly conformal radiotherapy may be achievable, even for 3DCRT treatments Further work involves investigating other variables not considered in this study, for example, rotation and deformation of the target and surrounding tissues and IMRT delivery. Though only a four-field technique was investigated here, we expect the insensitivity of the PTV, bladder, and rectum shown for the four-field technique to translate to other techniques as essentially the PTV, bladder, and rectum are maintaining a similar spatial relationship with respect to the treatment beam, independently of beam angle and intensity modulation. Another area of interest is combining the method to account for internal motion presented here with a related method to automatically use the beam to correct for patient-positioning errors. 25 The development of techniques to rapidly account for variations in the external pose of the patient and internal target and normal tissue motion could allow for significantly reduced patient-treatment time, in addition to high treatment accuracy. Avoiding the need to reposition the patient prior to or during treatment and reducing the overall treatment time are hypothesized to reduce the post-couch-movement secondary skeletal motion induced by couch motion or fatigue.
V. CONCLUSION
The dosimetric stability of a dynamic compensation strategy for correcting internal motion has been applied to conformal prostate radiotherapy. The compensation strategy included MLC aperture adjustment and MU adjustment and used a combination of information potentially available at delivery. The dose distribution to the target and critical organs moving with the target was robust to the motion. Variation in dose to organs moving independently of the target was necessarily observed.
